The University of Dundee, UK, has announced a collaboration with South Korean pharmaceutical company Bukwang to develop a new treatment for Parkinson’s.
Collaborating with researchers at the University of Oxford, UK, the university’s drug discovery unit (DDU) has found molecules that may reduce levels of a protein closely connected to the development of the condition.
The new partnership will build on this existing relationship between the universities – and facilitate a further three-year Parkinson’s research programme which will move the molecules towards clinical development.
Professor Paul Wyatt, head of the DDU, said: “Drug discovery for neurological disorders is especially challenging and an area where academia and industry need to be working together.
“This project brings together the clinical and translational research expertise in Oxford with Dundee’s professional drug-discovery capabilities, allowing us to move one stage further towards a treatment.”